Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.
Investigators at the University of Birmingham in the U.K. have published the results of a small but intriguing study that has highlighted the potential of Novo Nordisk's blockbuster diabetes drug Victoza (liraglutide) for NASH, an increasingly common liver disease.
Novo Nordisk, the Danish maker of insulin, said all of its global manufacturing facilities will run on electricity generated from renewable sources by 2020.
Danish drugmaker Novo Nordisk was hit by China's August devaluation of the yuan as well as domestic competition in the third quarter that poses a challenge to an otherwise strong franchise.
Novo Nordisk announced several months ago that it would invest $1.2 billion to build its first ingredient plant in the U.S., just one piece of a massive production buildup the company is undertaking around the world. Today it kicked off another, starting work on an insulin fill-and-finish plant in its home country of Denmark.
If you listen to drugmakers talk, the world diabetes market is fraught with peril. Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition, while Sanofi says its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which kicked off one piece of a huge production buildup on Wednesday.
Novo Nordisk CEO Lars Rebien Sørensen speaks of stingy payers and global competition in the world diabetes market, while Sanofi told investors its diabetes drug sales will fall through 2018. But none of this has deterred insulin specialist Novo, which today kicked off one piece of a huge production buildup that all told will add more than 1,200 jobs to the drugmaker.
U.S. payers have put the screws to diabetes drug prices. New launches have churned up stable drug classes. New outcomes data seem certain to shake things up, too. But diabetes-focused Novo Nordisk just keeps sailing along.
Novo Nordisk announced an expanded drug delivery partnership with Emisphere under which the Big Pharma will develop medications for metabolic disorders like diabetes and obesity using the partner's Eligen platform for oral medications.
Pennsylvania's Galera Therapeutics closed a $37 million Series B financing to advance its treatment for a common side effect of radiation therapy, bringing some big-name investors to the table.